# Cell counters and viability systems Bench-top instruments that automate cell counting and viability assessment — image-based dye-exclusion counters, fluorescence-based analyzers and closed-cassette systems — replacing manual hemocytometer counting for daily cell-culture QC, bioreactor process monitoring and cell-therapy/cell-line release testing. Source: https://en.bioecon.ru/technology/cell-counters-viability-systems/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: US FDA 21 CFR Part 11 + EU GMP Annex 11 for GxP cell-therapy and cell-line release testing | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)] Cell counters and viability systems automate what a manual hemocytometer count once did by hand: determining cell concentration and the live/dead fraction of a suspension, reported in seconds rather than the several minutes a trained technician needs per sample. Two detection principles dominate: image-based counting captures a bright-field or phase- contrast image of cells in a disposable slide or chamber and applies trypan-blue dye- exclusion image analysis to distinguish live from dead cells; fluorescence-based counting stains cells with a nucleic-acid dye and reads fluorescence intensity, extending the method to samples where dye exclusion alone is unreliable, such as highly viscous or debris-heavy suspensions. The instruments sit at every stage of a cell-culture workflow — a daily passage check in basic research, an in-process bioreactor sample during a monoclonal- antibody or cell-therapy run, and a release specification before a CAR-T or stem-cell product ships — and the shift from manual counting to automated systems has been driven largely by the reproducibility problem: operator-to-operator variation in manual hemocytometer counts commonly exceeds 20%, while an automated image-based system typically holds coefficient of variation under 10%. The key directions of cell counting and viability analysis are: 1. **Image-based dye-exclusion counting (Image-Based Counting):** disposable-slide bright-field imaging with trypan-blue exclusion, the default replacement for manual hemocytometer counting in general cell-culture QC. 2. **Fluorescence-based viability analysis (Fluorescence Viability):** nucleic-acid dye staining read by fluorescence detection, extending accurate counting to viscous, pigmented or debris-heavy samples where dye exclusion alone is unreliable. 3. **Closed-cassette and reagent-cartridge systems (Closed-System Counting):** self- contained fluidic cassettes that minimize user contact with the sample, reducing contamination risk for GMP cell-therapy manufacturing environments. 4. **In-line and at-line bioprocess counting (Bioprocess Counting):** compact counters integrated into or adjacent to a bioreactor sampling line for frequent viable-cell- density monitoring during a production run. ### Sectoral value chain ``` [Cell sample] ──> [Sample loading: slide/cassette] ──> [Imaging or fluorescence detection] ──> [Concentration + viability result] │ (QC/release record) │ ▼ [Culture-passage or release decision] <─── [Software: image analysis or fluorescence gating] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Sample preparation** | Cell suspension is mixed with trypan blue or a fluorescent viability dye, and diluted if needed to fall within the instrument's countable range. | **In:** raw cell suspension, dye reagent. **Out:** stained, dilution-ready sample. | | **Sample loading** | The stained sample is pipetted into a disposable counting slide or a reagent cartridge/cassette. | **In:** stained sample. **Out:** loaded slide or cassette ready for reading. | | **Detection** | Bright-field or phase-contrast imaging (image-based) or fluorescence excitation and emission capture (fluorescence-based) generates the raw per-cell signal. | **In:** loaded slide/cassette. **Out:** raw image or fluorescence intensity data. | | **Image or signal analysis** | Software identifies individual cells, classifies each as live or dead by dye uptake/exclusion, and measures diameter. | **In:** raw image/signal. **Out:** per-cell classification (live/dead, size). | | **Statistics and reporting** | Aggregated concentration (cells/mL), viability percentage and average diameter are calculated and logged. | **In:** per-cell classifications. **Out:** concentration, viability %, size distribution report. | | **Culture-passage or release decision** | Lab staff or a GxP release workflow compares the result against a passage threshold or release specification. | **In:** counting report. **Out:** passage/dilution decision or batch-release determination. | Cross-cutting technologies of the sector: - **AI-based cell segmentation:** machine-learning image-segmentation models improve counting accuracy for clumped, aggregated or morphologically atypical cell populations compared to classical edge-detection algorithms. - **Disposable counting-slide standardization:** pre-calibrated, single-use slides remove hemocytometer cleaning and chamber-depth calibration as sources of operator variability. - **Multi-parameter fluorescence panels:** newer instruments add apoptosis, cell-cycle or GFP-expression channels alongside viability on the same fluorescence-detection platform. --- ## US The US market centers on bioprocess and cell-therapy manufacturing, where accurate viable- cell-density counting is a routine in-process control, plus a concentration of the category's largest instrument brands. ### bioprocess viable-cell-density monitoring, cell-therapy release counting, general cell-culture QC - **Nexcelom (part of Revvity):** the Cellometer line (Auto 2000, K2, Ascend) offers dual-fluorescence bright-field counting with built-in assays for specific cell types, used across academic, biotech and cell-therapy manufacturing labs. - **Beckman Coulter:** the Vi-CELL BLU automates trypan-blue dye-exclusion counting with a 24-position sample carousel, reporting viability percentage, concentration and cell count for routine bioprocess and cell-culture QC. - **Thermo Fisher Scientific:** the Invitrogen Countess 3 and Countess 3 FL automated cell counters provide rapid bright-field and fluorescence-based counting and viability analysis for general cell-culture workflows. --- ## CN Shanghai Ruiyu Biotech's Countstar line is a confirmed China-headquartered instrument maker in this category — one of the few EQP-kind screens this session to clear with a domestic vendor rather than an import-only market. ### domestic instrument origination, marketplace-distributed low-cost counters, growing biomanufacturing demand - **Countstar (Shanghai Ruiyu Biotech):** the Countstar automated cell counter and fluorescence cell analyzer line (including the Countstar Mira FL) is sold through Chinese biotech-equipment marketplaces and Western laboratory-equipment distributors, with the Mira FL fluorescence analyzer confirmed at retail through an independent US distributor. - **Screening note:** evidence for this entity came primarily from marketplace listing titles rather than the vendor's own product pages, so specification claims are kept general rather than citing exact performance numbers. --- ## EU Denmark's ChemoMetec anchors Europe's contribution with a closed-cassette design distinct from the open-slide approach common among US competitors. ### closed-cassette fluidics, contamination-risk reduction for GMP environments, fluorescence-based viability - **ChemoMetec (Denmark):** the NucleoCounter line (NC-200, NC-203, NC-3000) and the newer XcytoMatic platform use a closed reagent-cassette design that limits user contact with the sample, positioned for consistent counting in regulated manufacturing environments. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Nexcelom** | 🇺🇸 USA | *Cellometer Auto 2000, K2, Ascend* | Dual-fluorescence bright-field counting (part of Revvity) | Commercial | | **ChemoMetec** | 🇩🇰 Denmark | *NucleoCounter NC-200/NC-203/NC-3000, XcytoMatic* | Closed-cassette fluidics; fluorescence-based viability | Commercial, public (CPH:CHEMM) | | **Beckman Coulter** | 🇺🇸 USA | *Vi-CELL BLU* | Automated trypan-blue exclusion; 24-position carousel (Danaher) | Commercial | | **Thermo Fisher Scientific** | 🇺🇸 USA | *Countess 3, Countess 3 FL* | Bright-field and fluorescence-based counting | Commercial, public (NYSE:TMO) | | **Countstar (Shanghai Ruiyu Biotech)** | 🇨🇳 China | *Countstar, Countstar Mira FL* | Fluorescence cell analysis; marketplace/distributor sales | Commercial | --- ## Tech stack and innovations The stack layers two detection physics — bright-field dye exclusion and fluorescence — on a common image-analysis or signal-processing software backbone, with cassette-based designs adding a contamination-control layer for regulated environments. 1. **Trypan-blue dye-exclusion imaging:** - Live cells with intact membranes exclude the trypan-blue dye and appear bright under bright-field imaging, while dead cells with compromised membranes take up the dye and appear dark. - Image-analysis software segments individual cells, applies the exclusion criterion per cell, and reports concentration and viability percentage typically in under a minute per sample. 2. **Fluorescence-based nucleic-acid staining:** - A cell-permeant or cell-impermeant fluorescent dye binds nucleic acids differentially based on membrane integrity, distinguishing live from dead cells by fluorescence intensity rather than optical dye exclusion. - Extends reliable counting to samples — pigmented, highly viscous, or debris-laden — where bright-field dye exclusion alone produces ambiguous results. 3. **Closed-cassette fluidics:** - A self-contained cassette pre-loads the counting chamber and reagent, minimizing direct user contact with the sample and the risk of cross-contamination between runs. - Suited to GMP cell-therapy manufacturing environments where documented, closed sample handling supports the broader aseptic-processing requirement. --- ## Value chains and production pipelines ### Industrial pipeline of a bioprocess viable-cell-density check (21 CFR Part 11 / EU GMP Annex 11) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Bioreactor sample pull │ ───> │ 2. Staining & dilution │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Image/signal analysis │ <─── │ 3. Slide/cassette loading │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Statistics & report │ ───> │ 6. Passage/release decision│ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Bioreactor sample pull A small-volume sample is drawn from the bioreactor or culture vessel through an aseptic sampling port, timed to the process schedule for viable-cell-density monitoring. #### Stage 2: Staining and dilution The sample is mixed with trypan blue or a fluorescent viability dye and diluted, if necessary, to bring the cell concentration within the instrument's validated counting range. #### Stage 3: Slide or cassette loading The prepared sample is loaded into a disposable counting slide or a closed reagent cassette, depending on the instrument platform. #### Stage 4: Image or signal analysis Bright-field imaging with dye-exclusion analysis or fluorescence detection generates raw per-cell data, which segmentation software classifies as live or dead. #### Stage 5: Statistics and report generation Cell concentration, viability percentage and average cell diameter are calculated and logged, with GxP-validated systems generating a 21 CFR Part 11-compliant audit-trail record. #### Stage 6: Passage or release decision The result is compared against a culture-passage threshold for routine process control or against a validated release specification for a cell-therapy or cell-line product, driving the next-step decision. ---